Smiley L E, Garvey M S
Department of Medicine, Animal Medical Center, New York, NY.
J Vet Intern Med. 1994 May-Jun;8(3):195-202. doi: 10.1111/j.1939-1676.1994.tb03215.x.
The purpose of this study was to evaluate the safety and efficacy of the synthetic colloid hetastarch in dogs with hypoalbuminemia. Individual doses of hetastarch ranged from 9 to 27 mL/kg, and multiple doses were used frequently. Total doses ranged from 9 to 59 mL/kg. Colloid oncotic pressure was measured in 13 dogs before and after treatment. Mean colloid oncotic pressure +/- SD was 9.32 +/- 2.35 mm Hg before treatment and 16.41 +/- 1.61 mm Hg in 8 healthy pet dogs used as controls. The difference in these values was significant (P < .001). There was a significant increase in mean colloid oncotic pressure after the first dose of hetastarch, but there was no relationship between the dose of hetastarch and the magnitude of increase in colloid oncotic pressure. Peripheral edema or body cavity transudates resolved or decreased in 83% of the dogs despite concurrent use of crystalloid fluid therapy. There was also no relationship between the dose of hetastarch and resolution of edema. Worsening of the results from coagulograms occurred in 5 of 18 dogs, and included increased prothrombin time (n = 1), increased partial thromboplastin time (n = 5), and decreased platelet count (n = 3). Bleeding that occurred in 3 dogs could not be directly attributed to the hetastarch. There was no relationship between the dose of hetastarch and worsening of the values in the coagulograms.
本研究的目的是评估合成胶体羟乙基淀粉对低白蛋白血症犬的安全性和有效性。羟乙基淀粉的单次剂量范围为9至27 mL/kg，且经常使用多次剂量。总剂量范围为9至59 mL/kg。在13只犬治疗前后测量了胶体渗透压。治疗前平均胶体渗透压±标准差为9.32±2.35 mmHg，在8只作为对照的健康宠物犬中为16.41±1.61 mmHg。这些值的差异具有显著性（P <.001）。首次给予羟乙基淀粉后，平均胶体渗透压显著升高，但羟乙基淀粉的剂量与胶体渗透压升高幅度之间没有关系。尽管同时使用了晶体液治疗，但83%的犬外周水肿或体腔漏出液消退或减少。羟乙基淀粉的剂量与水肿消退之间也没有关系。18只犬中有5只凝血图结果恶化，包括凝血酶原时间延长（n = 1）、部分凝血活酶时间延长（n = 5）和血小板计数减少（n = 3）。3只犬发生的出血不能直接归因于羟乙基淀粉。羟乙基淀粉的剂量与凝血图值恶化之间没有关系。
